tetano
Editor, Senior Moderator
Biol Pharm Bull
. 2020;43(12):1960-1965.
doi: 10.1248/bpb.b20-00543.
A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season
Yu Norikoshi[SUP] 1 [/SUP], Tokunori Ikeda[SUP] 2 3 [/SUP], Kodai Sasahara[SUP] 1 [/SUP], Mariko Hamada[SUP] 4 [/SUP], Erika Torigoe[SUP] 4 [/SUP], Mai Nagae[SUP] 5 [/SUP], Tomoe Tashiro[SUP] 5 [/SUP], Fukuko Horio[SUP] 2 [/SUP], Junji Saruwatari[SUP] 6 [/SUP], Yuji Uchida[SUP] 2 [/SUP], Makoto Anraku[SUP] 2 [/SUP]
Affiliations
Abstract
The novel anti-influenza virus agent baloxavir marboxil is a selective inhibitor of an influenza cap-dependent endonuclease. Although a single oral dose in tablet form of baloxavir marboxil is expected to improve drug compliance and rapidly reduce viral titers for pediatric patients with influenza, there is a concern that baloxavir marboxil-resistant influenza A variants could be generated. In this study, we investigated the frequency of prescription and pharmacy revisits for baloxavir marboxil at an outpatient clinic compared with that of neuraminidase inhibitors in pediatric patients with influenza. A total of 475 pediatric patients who were infected with the influenza virus visited the pharmacy between December 2019 and March 2020. Baloxavir marboxil (n = 149), oseltamivir (n = 161) and laninamivir (n = 162) were mainly prescribed and only a few patients were treated with peramivir (n = 2) or zanamivir (n = 1). Baloxavir marboxil-, oseltamivir- and laninamivir-treated pediatric patients were enrolled, and a log-rank test showed that the revisits of pediatric patients who were taking baloxavir marboxil was lower than those for oseltamivir (p < 0.001). Moreover, Cox proportional hazards models also revealed that baloxavir marboxil decreased the risk of revisits in comparison to oseltamivir (hazard ratio 0.28, 95% confidence interval 0.11-0.70, p = 0.006), while no difference was found between laninamivir and baloxavir marboxil. Although there is a need to acquire appropriate and relevant information concerning resistant viruses, our results suggest that baloxavir marboxil may be a useful drug for treating pediatric patients with influenza infections.
Keywords: baloxavir marboxil; influenza; neuraminidase inhibitor; pediatric patient; pharmacy.
. 2020;43(12):1960-1965.
doi: 10.1248/bpb.b20-00543.
A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season
Yu Norikoshi[SUP] 1 [/SUP], Tokunori Ikeda[SUP] 2 3 [/SUP], Kodai Sasahara[SUP] 1 [/SUP], Mariko Hamada[SUP] 4 [/SUP], Erika Torigoe[SUP] 4 [/SUP], Mai Nagae[SUP] 5 [/SUP], Tomoe Tashiro[SUP] 5 [/SUP], Fukuko Horio[SUP] 2 [/SUP], Junji Saruwatari[SUP] 6 [/SUP], Yuji Uchida[SUP] 2 [/SUP], Makoto Anraku[SUP] 2 [/SUP]
Affiliations
- PMID: 33268716
- DOI: 10.1248/bpb.b20-00543
Abstract
The novel anti-influenza virus agent baloxavir marboxil is a selective inhibitor of an influenza cap-dependent endonuclease. Although a single oral dose in tablet form of baloxavir marboxil is expected to improve drug compliance and rapidly reduce viral titers for pediatric patients with influenza, there is a concern that baloxavir marboxil-resistant influenza A variants could be generated. In this study, we investigated the frequency of prescription and pharmacy revisits for baloxavir marboxil at an outpatient clinic compared with that of neuraminidase inhibitors in pediatric patients with influenza. A total of 475 pediatric patients who were infected with the influenza virus visited the pharmacy between December 2019 and March 2020. Baloxavir marboxil (n = 149), oseltamivir (n = 161) and laninamivir (n = 162) were mainly prescribed and only a few patients were treated with peramivir (n = 2) or zanamivir (n = 1). Baloxavir marboxil-, oseltamivir- and laninamivir-treated pediatric patients were enrolled, and a log-rank test showed that the revisits of pediatric patients who were taking baloxavir marboxil was lower than those for oseltamivir (p < 0.001). Moreover, Cox proportional hazards models also revealed that baloxavir marboxil decreased the risk of revisits in comparison to oseltamivir (hazard ratio 0.28, 95% confidence interval 0.11-0.70, p = 0.006), while no difference was found between laninamivir and baloxavir marboxil. Although there is a need to acquire appropriate and relevant information concerning resistant viruses, our results suggest that baloxavir marboxil may be a useful drug for treating pediatric patients with influenza infections.
Keywords: baloxavir marboxil; influenza; neuraminidase inhibitor; pediatric patient; pharmacy.